Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma

Medical and Pediatric Oncology

Volumn 34, Issue 4, 2000, Pages 242-249

  Theis, Jochen G W ^a,b   Chan, Helen S L ^a,b   Greenberg, Mark L ^a,b   Malkin, David ^a,b   Karaskov, Vladimir ^a,b   Moncica, Ileana ^a,b   Koren, Gideon ^a,b   Doyle, John ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antineoplastic agents; Children; Combined clinical trials; Cyclosporine; P glycoprotein; Sarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACTINOMYCIN; ETOPOSIDE; GLYCOPROTEIN; IFOSFAMIDE; VINCRISTINE;

ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; STOMATITIS; TOXICITY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DACTINOMYCIN; ETOPOSIDE; FEMALE; FEVER; HUMANS; IFOSFAMIDE; MALE; NEUTROPENIA; P-GLYCOPROTEIN; PILOT PROJECTS; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; SARCOMA; SEPSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0034102806     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(200004)34:4<242::AID-MPO2>3.0.CO;2-U     Document Type: Article

References (39)

1. Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv 1986;5:25-46.
2. Gros P, Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-731.
3. Gerlach JH, Endicott JA, Juranka PF, et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986;324:485-489.
4. Chen C-J, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 1986;47:381-389.
5. Ueda K, Cardarelli C, Gottesman M, Pastan I. Expression of a full length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-3008.
6. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-424.
7. Bourhis J, Benard J, Hartmann O, et al. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. JNCI 1989;81: 1401-1405.
8. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
9. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-1614.
10. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 1992;79:473-476.
11. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer [review]. Pharmacol Rev 1990;42:155-199.
12. Yahanda AM, Alder KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992;10:1624-1634.
13. Sonneveld P, Durie BG, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 1992;340:255-259.
14. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10:1635-1642.
15. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-1660.
16. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993;53:4837-4842.
17. Samuels BL, Mick R, Vogelzang NJ, et al. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther 1993;54:421-429.
18. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12:835-842.
19. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86: 695-698.
20. Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-1287.
21. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-2734.
22. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986;11:107-132.
23. Chan HS, DeBoer G, Haddad G, Ling V. Multidrug drug resistance in pediatric sarcomas. Hematol Oncol Clin North Am 1995; 9:889-908.
24. Chan HSL, Thorner PS, Weitzman S, et al. Cyclosporin A for reversal of multidrug resistance in childhood malignancies. Proc Am Assoc Cancer Res 1992;33:478.
25. Chan HSL, DeBoer G, Koren G, et al. Cyclosporin A modulated chemotherapy with focal therapy: a new approach to retinoblastoma. Proc Amer Assoc Cancer Res 1994;35:359.
26. Rozencweig M, Stagnet M, Hansen HH, et al. EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee. Eur J Cancer Clin Oncol 1985;21: 1005-1007.
27. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study - I. A final report. Cancer 1988;61: 209-220.
28. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-1198.
29. Theis JGW, Liau-Chu M, Chan HSL, et al. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol 1995;13:2508-2516.
30. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995;9:363-382.
31. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interaction of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43:630-635.
32. Relling MV, Nemec J, Schuetz EG, et al. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994;45:352-358.
33. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53:5629-5637.
34. Kim JH, Perfect JR. Infection and cyclosporine. Rev Infect Dis 1989;11:677-690.
35. Benigni A, Morigi M, Perico N, et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 1992;54:775-780.
36. Haller H, Spies K, Lindschau C, et al. The effect of cyclosporine on calcium, protein kinase C, and sodium-proton exchange in platelets. Transplantation 1994;57:1516-1520.
37. Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin. J Clin Invest 1995;96:1698-705.
38. van Kalken CK, Broxterman HJ, Pinedo HM, et al. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993;67:284-289.
39. Ost L. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. Transplantation 1987;44:533-535.